MINIPRESS Drug Patent Profile

Which patents cover Minipress, and what generic alternatives are available?

Minipress is a drug marketed by Pfizer and is included in two NDAs.

The generic ingredient in MINIPRESS is prazosin hydrochloride. There are seventeen drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the prazosin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Minipress

A generic version of MINIPRESS was approved as prazosin hydrochloride by TEVA PHARMS on September 12^th, 1988.

Summary for MINIPRESS

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	117
Clinical Trials:	27
Patent Applications:	1,850
Drug Prices:	Drug price information for MINIPRESS
What excipients (inactive ingredients) are in MINIPRESS?	MINIPRESS excipients list
DailyMed Link:	MINIPRESS at DailyMed

See drug prices for MINIPRESS

Recent Clinical Trials for MINIPRESS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yale University	Phase 1/Phase 2
University of Washington	Phase 4
Johns Hopkins University	Phase 2

See all MINIPRESS clinical trials

US Patents and Regulatory Information for MINIPRESS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-002	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Pfizer	MINIPRESS XL	prazosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019775-001	Jan 29, 1992		DISCN	No	No
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-003	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes

Expired US Patents for MINIPRESS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-003	Approved Prior to Jan 1, 1982
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-001	Approved Prior to Jan 1, 1982
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-001	Approved Prior to Jan 1, 1982

International Patents for MINIPRESS

See the table below for patents covering MINIPRESS around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	86877
Belgium	868843
Sweden	7701624

MINIPRESS Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory for Minipress

Introduction

Minipress, a brand name for the drug Prazosin, is a significant player in the anti-hypertensive drugs market. It is used to treat hypertension and other conditions such as benign prostatic hyperplasia. Here, we will delve into the market dynamics and financial trajectory of Minipress, highlighting key factors influencing its market position.

Market Size and Growth of Anti-Hypertensive Drugs

The global anti-hypertensive drugs market, within which Minipress operates, was estimated at USD 23.57 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 3.91% from 2024 to 2030, reaching USD 30.69 billion by 2030[1].

Segment Performance

Minipress falls under the category of alpha-blockers, which, while not the largest segment, is part of a broader market driven by increasing prevalence of hypertension and a growing geriatric population. The ACE inhibitors segment, however, is expected to grow at the fastest CAGR of 4.96% over the forecast period, due to their cost-effectiveness and wide prescription for cardiovascular diseases and other chronic conditions[1].

Route of Administration

The oral segment, which includes Minipress, held the largest market share of 75.40% in 2023. This dominance is attributed to patient preference for oral medications and the growing demand for fixed-dose combinations of anti-hypertensive drugs. Pharmaceutical companies continue to develop new oral anti-hypertensive drugs with improved efficacy and safety profiles, further driving this segment's growth[1].

Regional Market

North America, where Minipress is widely available, accounted for the largest revenue share of 37.55% in 2023. The region's growth is driven by the easy availability of anti-hypertensive drugs, the development of new and more effective treatments, and a surge in the incidence of hypertension and obesity[1].

Competitive Landscape

Minipress, manufactured by Pfizer, operates in a competitive market with other major players such as Sanofi, Boehringer Ingelheim International GmbH, Novartis AG, and AstraZeneca. The market is characterized by strategic initiatives including collaborations, geographic expansion, and strategic agreements to expand product portfolios and maximize market share[1].

Recent Developments

In March 2023, Alembic Pharmaceuticals Limited received FDA approval for Prazosin Hydrochloride Capsule, which is therapeutically equivalent to Pfizer’s Minipress Capsules. This development indicates increasing competition in the generic segment, which could impact the market share of branded drugs like Minipress[1].

Financial Performance

Pfizer, the manufacturer of Minipress, has reported significant financial performance in recent years. The company's key brands, including Minipress, have delivered remarkable growth. For instance, in the annual report for 2023-24, Pfizer highlighted that Minipress, along with other key brands like Prevenar and Eliquis, contributed to double-digit growth and significant volume increases[2].

Impact of Generic Competition

The entry of generic versions of anti-hypertensive drugs, including Prazosin, can significantly impact the financial trajectory of branded drugs like Minipress. Generic drugs tend to cost less and often lead to a shift in utilization from brand to generic alternatives. This shift can result in a decrease in the average wholesale price (AWP) and an increase in generic dispensing rates (GDRs), which can exceed 90% for drugs with generic options available[3].

Pricing Dynamics

The pricing of Minipress and other anti-hypertensive drugs is influenced by various factors, including rebates and discounts. For example, the median AWP discount experience for brand drug claims can be around 18%, while generic drugs can see discounts of up to 83%. The presence of generic competitors can lead to increased rebate payments by manufacturers to incentivize preference for the brand drug over its generic counterpart[3].

Regulatory and Market Strategies

To maintain market share, pharmaceutical companies like Pfizer are focusing on strategic initiatives such as expanding sales and distribution footprints, launching new SKUs, and sharpening marketing initiatives. Additionally, companies are adjusting their internal structures to reflect market needs, such as creating focused teams for adult vaccination awareness[2].

Environmental, Social, and Governance (ESG) Considerations

Pfizer, like other pharmaceutical companies, is also focusing on ESG initiatives. The company is committed to addressing health and environmental issues, such as climate change, and has made significant strides in using renewable energy sources for its manufacturing operations[2].

Key Takeaways

• Market Growth: The anti-hypertensive drugs market, including Minipress, is expected to grow at a CAGR of 3.91% from 2024 to 2030.
• Competition: The entry of generic versions and strategic initiatives by competitors are key factors influencing the market dynamics.
• Financial Performance: Minipress has contributed to Pfizer's financial growth, but faces challenges from generic competition.
• Pricing Dynamics: Rebates and discounts play a crucial role in the pricing strategy for Minipress and other anti-hypertensive drugs.
• ESG Initiatives: Pharmaceutical companies are increasingly focusing on ESG considerations to sustain their operations and reputation.

FAQs

Q: What is the expected growth rate of the global anti-hypertensive drugs market? A: The global anti-hypertensive drugs market is expected to grow at a CAGR of 3.91% from 2024 to 2030[1].

Q: Which segment is expected to grow the fastest in the anti-hypertensive drugs market? A: The ACE inhibitors segment is expected to grow at the fastest CAGR of 4.96% over the forecast period[1].

Q: How does the entry of generic versions impact the market share of branded drugs like Minipress? A: The entry of generic versions can lead to a significant shift in utilization from brand to generic alternatives, resulting in decreased market share for branded drugs[3].

Q: What are the key factors driving the growth of the anti-hypertensive drugs market in North America? A: The growth in North America is driven by the easy availability of anti-hypertensive drugs, the development of new treatments, and a surge in the incidence of hypertension and obesity[1].

Q: How are pharmaceutical companies like Pfizer adapting to market changes? A: Companies are focusing on expanding their sales and distribution footprints, launching new SKUs, sharpening marketing initiatives, and adjusting internal structures to reflect market needs[2].

Sources

1. Grand View Research - Anti-hypertensive Drugs Market Size & Share Report 2030
2. Pfizer Limited - Annual Report 2023 – 24
3. Milliman - Commercial drug trends: 2024 release
4. Federal Trade Commission - Generic Drug Industry Dynamics
5. Congress.gov - Congressional Record (not relevant to the topic)